Loading quotes...
Forecast
The analysts' average price target is €6.55 (+49.20%). The median is €5.71 (+30.07%).
| Buy |
3 |
| Hold |
7 |
| Sell |
2 |
News Go to news feed
RxSight unveils turnaround plan and strengthens partnership with Alcon
At the Wells Fargo Healthcare Conference, new CEO Aziz Mottiwala presented a strategic realignment plan to intensify use of the light‑adjustable lens (LAL) among existing surgeons and to double U.S. sales through internal reallocations. The partnership closed in July with Alcon includes a $200 million upfront payment and a 30% royalty on future sales, plus access to Alcon’s sales network. RxSight has about $210 million in cash (excluding the full Alcon payment), high gross margins, and is working on a next‑generation LAL; the company is targeting a return to growth in 2027 but has not provided concrete forecasts. » More on de.investing.com
RxSight appoints Aziz Mottiwala as president and CEO
RxSight appointed Aziz Mottiwala, effective July 20, as president and chief executive officer; he replaces Dr. Ron Kurtz, who will move to chief medical officer and leave the board of directors, while Mottiwala will be named to the board. Mottiwala joins from Tarsus Pharmaceuticals and brings experience in senior sales and commercial roles in ophthalmology. The stock is under pressure (about −8% last week, −50% over six months) and is trading at $5.25 (market capitalization $216.92 million). The company manufactures the Light Adjustable Lens System and said it would not change its prior financial guidance. » More on de.investing.com
RxSight cuts 2026 revenue forecast after competitive pressure
RxSight lowered its 2026 revenue forecast to $110–120 million (previously $120–135 million), triggering a roughly 12.9% share price decline. The total revenue outlook of $140–160 million includes $30–40 million from the Alcon collaboration; preliminary Q2 revenues are expected at $32–34 million ( $5–7 million from the Alcon partnership, about $27 million from product sales). The company cited "significant commercial headwinds" and plans to accelerate sales investments while maintaining spending discipline; gross margin guidance was raised to 73–75%, and operating expenses remain at the high end of the $150–160 million range. Cash and equivalents totaled about $209 million as of June 30; RxSight is working on a next generation of Light Adjustable Lens products. » More on de.investing.com
Financials
| (EUR) | June 2026 | YoY |
|---|---|---|
| Revenue | 29.56m | 3.59% |
| Gross profit | 22.68m | 6.13% |
| Net profit | -10.6m | 6.00% |
| EBITDA | -9.64m | 3.60% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €185.31m |
Number of shares | 41.59m |
52-week high/low | €11.85 - €3.94 |
| Dividends | No |
Beta | 1.14 |
P/E ratio | -4.40 |
PEG ratio | 0.13 |
P/B ratio | 0.78 |
P/S ratio | 1.62 |
Company profile
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Name | RXSIGHT INC. DL -,001 |
| CEO | Aziz Mottiwala |
| Headquarters | Aliso Viejo,
ca USA |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 30/07/2021 |
| Employees | 461 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | RXST |